Written questions by Morgan.

What steps he is taking to improve (a) diagnosis and (b) care of Placenta Accreta Spectrum.

The diagnosis of placenta accreta spectrum is primarily done in the antenatal period using ultrasound imaging. To ensure effective diagnosis and management of placenta accreta spectrum, national guidance is provided within the National Institute for Health and Care Excellence (NICE) guidance and the Royal College of Obstetricians and Gynaecologists’ Placenta Praevia and Placenta Accreta: Diagnosis and Management Guideline. The NICE guidance and the Royal College of Obstetricians and Gynaecologists’ guidelines are available, respectively, at the following two links:https://www.nice.org.uk/guidance/ng192/documents/draft-guideline-2https://www.rcog.org.uk/guidance/browse-all-guidance/green-top-guidelines/placenta-praevia-and-placenta-accreta-diagnosis-and-management-green-top-guideline-no-27a/In 2020, NHS England commissioned placenta accreta networks in the United Kingdom to support local and regional screening, shared protocols, and co-ordinated referral pathways to specialist pregnancy accreta centres. These centres consist of highly experienced multidisciplinary teams with the expertise to manage this condition and improve the safety outcomes for women and babies.

Whether he has made an assessment of the potential impact of NHS spending on pharmaceutical products on NHS service provision in the context of the UK-US trade deal.

By increasing the standard National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold, we are increasing the value that we place on innovations that deliver improvements to patient health. Alongside the changes that we announced in the Life Sciences Sector Plan, this will increase both the speed and breadth of patient access to innovative medicines and encourage growth in United Kingdom-based clinical trials.Costs will start smaller but will increase over time as the NICE approves more life improving and lifesaving medicines. Total costs over the Spending Review period are expected to be approximately £1 billion. But the final costs will depend on which medicines NICE decides to approve and the actual uptake of these.This deal is a vital investment that builds on the strength of our National Health Service and world leading life sciences sector to increase access to life-changing medicines without taking essential funding from our frontline NHS services. We will always prioritise the needs of NHS patients and at the Spending Review we delivered a record real terms increase for day-to-day spending for the NHS in England up to April 2029.This deal will be funded by allocations made at the Spending Review, where front line services will remain protected through the record funding secured. Future year funding will be settled at the next Spending Review.

When he expects fax machines to be phased out of use in Shrewsbury and Telford Hospital NHS Trust.

My Rt Hon. Friend, the Secretary of State for Health and Social Care, has instructed National Health Service trusts to stop using fax machines for anything other than business continuity. The trust has informed NHS England that they currently only use fax machines for administrative tasks.NHS England will be meeting with the Shrewsbury and Telford Hospital NHS Trust to work with them on their decommissioning plans. As such, there is currently no date set for when fax machines will be phased out.

What recent assessment he has made of the use of fax machines by Shrewsbury and Telford Hospital NHS Trust.

My Rt Hon. Friend, the Secretary of State for Health and Social Care, has instructed National Health Service trusts to stop using fax machines for anything other than business continuity. The trust has informed NHS England that they currently only use fax machines for administrative tasks.NHS England will be meeting with the Shrewsbury and Telford Hospital NHS Trust to work with them on their decommissioning plans. As such, there is currently no date set for when fax machines will be phased out.

What steps he is taking to incorporate the National Audit Office recommendations regarding the 2023 Long Term Workforce Plan into the development of the 10 Year Workforce Plan.

The 10 Year Workforce Plan will ensure the National Health Service has the right people in the right places, with the right skills to care for patients, when they need it.To address the National Audit Office’s recommendations regarding the 2023 Long Term Workforce Plan, updated workforce modelling and its underlying assumptions will be set out in and alongside the new plan when published in spring 2026. It will be supported by external independent scrutiny.We are committed to engagement with external stakeholders. On the 26 September 2025 we launched a formal call for evidence, which provided stakeholders the opportunity to contribute directly to the plan’s development. This closed on 7 November 2025. The submissions to our call for evidence are being analysed to inform the development of the plan.

What assessment his Department has made of the National Audit Office recommendations in its analysis of the 2023 Long Term Workforce Plan (a) in general and (b) specifically the recommendation that assumptions should be generated in transparent and systematic consultation with external stakeholders.

The 10 Year Workforce Plan will ensure the National Health Service has the right people in the right places, with the right skills to care for patients, when they need it.To address the National Audit Office’s recommendations regarding the 2023 Long Term Workforce Plan, updated workforce modelling and its underlying assumptions will be set out in and alongside the new plan when published in spring 2026. It will be supported by external independent scrutiny.We are committed to engagement with external stakeholders. On the 26 September 2025 we launched a formal call for evidence, which provided stakeholders the opportunity to contribute directly to the plan’s development. This closed on 7 November 2025. The submissions to our call for evidence are being analysed to inform the development of the plan.

What steps he is taking to help (a) increase capacity for and (b) reduce inequalities in access to respiratory diagnosis.

Community diagnostic centres (CDCs) are increasing capacity and access to respiratory diagnostic tests such as spirometry and fractional exhaled nitric oxide, and will continue to do so as more sites come online. For example, the first five months of 2025/26 saw an increase in CDC spirometry testing of approximately 2,000 tests per month more than in the previous year.In addition, 101 CDCs across the country now offer out-of-hours services 12 hours a day, seven days a week, meaning patients across the country can access vital diagnostic tests around busy working lives.

If his Department will take steps to help ensure that health boards and trusts collect and publish data on the provision of respiratory diagnostics.

I refer the Hon. Member to the answer I gave to the Hon. Member for Chelmsford on 27 October 2025 to Question 83430.

What steps he is taking to help reduce the potential impact of chronic respiratory conditions on the NHS this winter.

NHS England, working with the Department, the UK Health Security Agency, and other partners, is taking action to reduce the impact of respiratory conditions on the National Health Service this winter. This includes robust, consistent Infection Prevention and Control measures, and a campaign to encourage eligible people to get their winter vaccinations. Further details of the actions being taken to reduce demand on acute services during winter are available at the following link:https://www.england.nhs.uk/long-read/urgent-and-emergency-care-plan-2025-26/

If he will outline the criteria used to decide which conditions should receive a modern service framework; and whether respiratory health meets these criteria.

I refer the hon. Member to the answer I gave to the hon. Member for Lewes on 27 October 2025 to Question 82544.

If his Department will make an assessment of the potential merits of commissioning neighbourhood level respiratory diagnostic hubs.

Respiratory diagnostic hubs have been piloted and developed in many parts of England and this learning will inform the development of more neighbourhood health services.Community diagnostic centres (CDCs) are also supporting the shift to neighbourhood health, with 170 CDCs now being operational across England. All standard model CDCs are required to offer a range of diagnostic tests that support diagnosis of respiratory conditions, including spirometry and lung function tests.CDCs offer local populations a wide range of diagnostic tests closer to home and greater choice on where and how they are undertaken, reducing the need for hospital visits and speeding up diagnosis, whilst also reducing pressure on hospitals.We are continuing to invest in expanding diagnostic capacity in the National Health Service, including through increasing CDC capacity. As set out in the Elective reform Plan, we plan to build up to five more CDCs, as part of £600 million capital funding for diagnostics in 2025/26. We are also increasing the operating hours of existing sites so that more offer services 12 hours a day, seven days a week.

If he will take steps to support educators, supervisors, mentors and trainers in the 10 Year Workforce Plan and work with employers to increase capacity for medical education and training.

On 8 December, the Government put an offer in writing to the British Medical Association Resident Doctors Committee (BMA RDC) which was rejected. The offer would have increased the number of specialty training posts over the next three years from the 1,000 announced in the 10-Year Health Plan to 4,000, bringing forward 1,000 of these specialty training posts to start in 2026. The BMA have rejected the Government's offer, so that is not going ahead. Our door remains open, and this Government is determined to put an end to these damaging cycles of disruption. On 8 January 2026, my Rt. Hon. Friend, the Secretary of State for Health and Social Care, met with the BMA RDC to kick off a series of talks to resolve the dispute.The 10 Year Workforce Plan will ensure that the National Health Service has the right people in the right places, with the right skills to care for patients, when they need it. It will include modelling of the potential size and shape of the future workforce and implications for major professions.We are engaging with partners throughout this process, including universities and higher education institutes. A number of organisations with expertise in higher education were invited to and attended a ministerially led partner event on 5 November. As we continue the open and wide-ranging conversations we’ve been having with staff, patients and organisations across the country, we will ensure that the engagement is robust and representative of different stakeholder groups.

If the 10 Year Workforce Plan will expand the number of medical specialty training places to meet population demand, beyond the 1,000 proposed in the 10 Year Health Plan.

On 8 December, the Government put an offer in writing to the British Medical Association Resident Doctors Committee (BMA RDC) which was rejected. The offer would have increased the number of specialty training posts over the next three years from the 1,000 announced in the 10-Year Health Plan to 4,000, bringing forward 1,000 of these specialty training posts to start in 2026. The BMA have rejected the Government's offer, so that is not going ahead. Our door remains open, and this Government is determined to put an end to these damaging cycles of disruption. On 8 January 2026, my Rt. Hon. Friend, the Secretary of State for Health and Social Care, met with the BMA RDC to kick off a series of talks to resolve the dispute.The 10 Year Workforce Plan will ensure that the National Health Service has the right people in the right places, with the right skills to care for patients, when they need it. It will include modelling of the potential size and shape of the future workforce and implications for major professions.We are engaging with partners throughout this process, including universities and higher education institutes. A number of organisations with expertise in higher education were invited to and attended a ministerially led partner event on 5 November. As we continue the open and wide-ranging conversations we’ve been having with staff, patients and organisations across the country, we will ensure that the engagement is robust and representative of different stakeholder groups.

What the timetable is for the publication of the new nutrient profiling model announced in the 10-year health plan for England.

As set out in our 10-Year Health Plan for England: fit for the future, we will take decisive action on the obesity crisis, easing the strain on our National Health Service and creating the healthiest generation of children ever.  The plan also stated that the Nutrient Profiling Model (NPM) 2004/05, which underpins the advertising restrictions on ‘less healthy’ food and drink products on television and online and promotion restrictions on ‘less healthy’ food and drink products in stores and their equivalent places online, is out of date. Updating the standards to reflect the latest dietary advice will strengthen the restrictions and more effectively target the products of most concern to childhood obesity.The Government intends to publish the new NPM in due course, ahead of consulting on its application to the advertising and promotions restrictions this year.

Whether he has made an assessment of the potential impact of NHS spending on pharmaceutical products on levels of NHS staffing, equipment and activity in the context of the UK-US trade deal.

Every patient deserves access to the best possible treatment. By increasing the standard National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold, we are increasing the value that we place on innovations that deliver improvements to patient health. Alongside the changes that we announced in the Life Sciences Sector Plan this will increase both the speed and breadth of patient access to innovative medicines and encourage growth in United Kingdom based clinical trials. This is supported by confirmation that, thanks to strong UK support for innovation, the UK has secured mitigations under the United States of America’s ‘Most Favoured Nation’ drug pricing initiative.This deal will also benefit our life sciences sector, driving jobs, investment, and growth. We have secured a preferential tariff rate of 0% for all pharmaceuticals exports to the US for at least three years, and preferential terms for the UK’s medical technology exports, meaning no additional new tariffs on medical technology.The move has secured the confidence of the pharmaceutical industry that the UK is a top destination for investment and growth, with major firms like Moderna, Prologis, and BioNTech investing billions here, and renewed confidence in the UK.Costs will start smaller but will increase over time as NICE approves more life improving and lifesaving medicines. Total costs over the spending review period are expected to be approximately £1 billion. But the final costs will depend on which medicines NICE decides to approve and the actual uptake of these.

Whether he has made an assessment of the potential impact of NHS spending on pharmaceutical products on the economy in the context of the UK-US trade deal.

Every patient deserves access to the best possible treatment. By increasing the standard National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold, we are increasing the value that we place on innovations that deliver improvements to patient health. Alongside the changes that we announced in the Life Sciences Sector Plan this will increase both the speed and breadth of patient access to innovative medicines and encourage growth in United Kingdom based clinical trials. This is supported by confirmation that, thanks to strong UK support for innovation, the UK has secured mitigations under the United States of America’s ‘Most Favoured Nation’ drug pricing initiative.This deal will also benefit our life sciences sector, driving jobs, investment, and growth. We have secured a preferential tariff rate of 0% for all pharmaceuticals exports to the US for at least three years, and preferential terms for the UK’s medical technology exports, meaning no additional new tariffs on medical technology.The move has secured the confidence of the pharmaceutical industry that the UK is a top destination for investment and growth, with major firms like Moderna, Prologis, and BioNTech investing billions here, and renewed confidence in the UK.Costs will start smaller but will increase over time as NICE approves more life improving and lifesaving medicines. Total costs over the spending review period are expected to be approximately £1 billion. But the final costs will depend on which medicines NICE decides to approve and the actual uptake of these.

Whether he has made an assessment of the potential impact of NHS spending on pharmaceutical products on patients in the context of the UK-US trade deal.

Every patient deserves access to the best possible treatment. By increasing the standard National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold, we are increasing the value that we place on innovations that deliver improvements to patient health. Alongside the changes that we announced in the Life Sciences Sector Plan this will increase both the speed and breadth of patient access to innovative medicines and encourage growth in United Kingdom based clinical trials. This is supported by confirmation that, thanks to strong UK support for innovation, the UK has secured mitigations under the United States of America’s ‘Most Favoured Nation’ drug pricing initiative.This deal will also benefit our life sciences sector, driving jobs, investment, and growth. We have secured a preferential tariff rate of 0% for all pharmaceuticals exports to the US for at least three years, and preferential terms for the UK’s medical technology exports, meaning no additional new tariffs on medical technology.The move has secured the confidence of the pharmaceutical industry that the UK is a top destination for investment and growth, with major firms like Moderna, Prologis, and BioNTech investing billions here, and renewed confidence in the UK.Costs will start smaller but will increase over time as NICE approves more life improving and lifesaving medicines. Total costs over the spending review period are expected to be approximately £1 billion. But the final costs will depend on which medicines NICE decides to approve and the actual uptake of these.

What steps his Department plans to take to implement the healthy food standard policy announced as part of the 10-year health plan for England within the current Parliament; and if he will publish a timeline for these legislative or regulatory changes.

As set out in the 10-Year Health Plan, we will take decisive action on the obesity crisis, easing the strain on our National Health Service and creating the healthiest generation of children ever. The plan committed to introducing mandatory healthy food sales reporting for all large companies in the food sector before the end of this Parliament and targets to increase the healthiness of sales in all communities.To fulfil this commitment, the Government is working towards a Spring 2026 public consultation on Healthier Food Targets and Reporting. Implementation dates will be determined following consultation. We are engaging with stakeholders on how this policy could reduce health inequalities and will also consider this through consultation.We are considering the most suitable way to enforce the policy, and any decisions are subject to consultation.

How he plans to enforce the targets set for businesses under the new healthy food standard policy announced as part of the 10-year health plan for England.

As set out in the 10-Year Health Plan, we will take decisive action on the obesity crisis, easing the strain on our National Health Service and creating the healthiest generation of children ever. The plan committed to introducing mandatory healthy food sales reporting for all large companies in the food sector before the end of this Parliament and targets to increase the healthiness of sales in all communities.To fulfil this commitment, the Government is working towards a Spring 2026 public consultation on Healthier Food Targets and Reporting. Implementation dates will be determined following consultation. We are engaging with stakeholders on how this policy could reduce health inequalities and will also consider this through consultation.We are considering the most suitable way to enforce the policy, and any decisions are subject to consultation.

What steps he is taking to ensure that the healthy food standard policy will reduce health inequalities and improve access to healthy food for deprived communities.

As set out in the 10-Year Health Plan, we will take decisive action on the obesity crisis, easing the strain on our National Health Service and creating the healthiest generation of children ever. The plan committed to introducing mandatory healthy food sales reporting for all large companies in the food sector before the end of this Parliament and targets to increase the healthiness of sales in all communities.To fulfil this commitment, the Government is working towards a Spring 2026 public consultation on Healthier Food Targets and Reporting. Implementation dates will be determined following consultation. We are engaging with stakeholders on how this policy could reduce health inequalities and will also consider this through consultation.We are considering the most suitable way to enforce the policy, and any decisions are subject to consultation.